Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 11, 2006

GSK Submits SDA for Advair in COPD

  • GlaxoSmithKline submitted a supplemental new drug application to expand labeling for Advair Diskus® (fluticasone propionate and salmeterol inhalation powder), based on studies that showed reduced death risk and rate of chronic obstructive pulmonary disease (COPD) exacerbations.

    Results from GSK’s three-year TORCH study (TOwards a Revolution in COPD Health) showed a 17.5% reduction in risk of death from any cause over three years for patients receiving Advair 500/50 as compared with patients on placebo(p=0.052). In addition, it reduced the rate of COPD exacerbations by 25% compared with placebo (p<0.001). Advair also improved quality of life when compared to placebo (p<0.001), although it did not meet the predefined magnitude of difference.

    The company observed, however, that Advair was associated with increased reporting of pneumonia compared with placebo (p<0.001). Other adverse events (e.g. candidiasis, dysphonia, contusion) generally appear consistent with those seen in previous studies of Advair in patients with COPD.

    Advair 250/50 is currently indicated for the maintenance treatment of airflow obstruction in patients with COPD associated with chronic bronchitis.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »